Table 2 Laboratory examination between the progressive and Stable patients
From: The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China
Normal Range | Total (N = 323) | Progressive (N = 70) | Stable (N = 253) | P value | |
|---|---|---|---|---|---|
Blood cell count and lymphocyte classification | |||||
White blood Cell (× 109/L) | 3.5–9.5 | 4.57 (3.55–5.65) | 4.39 (3.62–5.72) | 4.60 (3.57–5.63) | 0.672 |
Neutrophils (× 109/L) | 1.8–6.3 | 2.56 (1.86–3.45) | 2.84 (2.13–4.19) | 2.52 (1.79–3.38) | 0.026 |
Lymphocytes (× 109/L) | 1.1–3.2 | 1.27 (0.99–1.73) | 1.02 (0.84–1.23) | 1.38 (1.07–1.85) | < 0.001 |
NLR | 1.90 (1.28–2.88) | 2.72 (1.87–4.37) | 1.72 (1.19–2.53) | < 0.001 | |
Hemoglobin (g/L) | 115–150 | 136.0 (127.0–146.0) | 138.0 (128.5–148.5) | 136.0 (127.0–146.0) | 0.223 |
Platelets (109/L) | 125–350 | 180.0 (143.0–224.0) | 147.0 (122.5–181.0) | 190.5 (154.0–238.0) | < 0.001 |
T lymphocyte (N) | 770–2041 | 980.0 (650.0–1317) | 529.0 (387.0–712.5) | 1071 (772.5–1399) | < 0.001 |
CD4 cell (N) | 500–1500 | 525.0 (361.0–714.0) | 302.0 (204.5–383.0) | 596.5 (452.5–757.0) | < 0.001 |
CD8 cell (N) | 356.0 (224.5–515.0) | 201.0 (134.5–294.0) | 402.5 (273.0–546.5) | < 0.001 | |
CD4/CD8 | 1.5–2.5 | 1.49 (1.09–1.96) | 1.61 (1.02–1.94) | 1.48 (1.12–1.96) | 0.907 |
Blood biochemistry | |||||
Total bilirubin (uM) | 1.7–21 | 9.80 (7.60–14.6) | 10.4 (8.10–16.0) | 9.55 (7.45–14.35) | 0.303 |
ALT (U/L) | < 45 | 20.0 (15.0–30.1) | 26.0 (19.0–38.3) | 19.0 (13.0–27.0) | < 0.001 |
AST (U/L) | < 45 | 26.0 (21.0–35.0) | 30.0 (23.5, 42.2) | 25.0 (20.0–33.0) | < 0.001 |
GGT (U/L) | < 49 | 24.0 (15.3–39.0) | 38.0 (23.0–62.0) | 21.3 (14.5–32.0) | < 0.001 |
ALP (U/L) | 35–100 | 60.0 (50.0–78.0) | 59.0 (48.9–72.5) | 60.5 (51.0–82.0) | 0.101 |
Potassium (mM) | 3.5–5.5 | 3.89 (3.62–4.15) | 3.80 (3.53–4.09) | 3.90 (3.64–4.17) | 0.031 |
Sodium (mM) | 135–145 | 138.2 (136.5–139.7) | 136.2 (134.7–139.1) | 138.4 (137.1–139.8) | < 0.001 |
BUN (mM) | 2.6–7.5 | 3.92 (3.20–4.92) | 4.78 (3.66–5.84) | 3.80 (3.13–4.67) | < 0.001 |
Cr (uM) | 41–73 | 62.0 (49.9–75.0) | 71.0 (61.8–94.0) | 58.0 (48.0–73.0) | < 0.001 |
eGFR (ml/min) | 90–250 | 108.6 (96.2–119.7) | 94.6 (77.0–105.6) | 111.2 (98.0–121.2) | < 0.001 |
Troponin T (ug/L) | < 0.012 | 0.012 (0,006–0.012) | 0.012 (0.012–0.013) | 0.012 (0.006–0.012) | < 0.001 |
Creatine kinase | 18.0–198.0 | 69.5 (50.0–96.0) | 82.5 (56.0–126.0) | 67.0 (48.5–90.5) | 0.099 |
CK-MB (ng/mL) | 0–2.37 | 0.54 (0.22–1.06) | 0.62 (0.22–1.19) | 0.55 (0.22–1.07) | 0.426 |
LDH (U/L) | 153 | 218.0 (174.0–379.0) | 283.0 (199.0–577.0) | 207.0 (166.0–323.0) | < 0.001 |
Infection-related parameters | |||||
ESR (s) | 0–20 | 30.0 (15.0–49.0) | 34.5 (26.0–51.0) | 23.5 (13.0–43.0) | < 0.001 |
CRP (mg/L) | < 8 | 9.9 (3.84–26.2) | 26.64 (10.4–48.6) | 7.25 (2.80–19.07) | < 0.001 |
PCT (ng/mL) | < 0.1 | 0.04 (0.03–0.06) | 0.06 (0.05–0.09) | 0.03 (0.02–0.05) | <0.001 |
IL-6 (pg/mL) | < 7 | 10.6 (4.12–19.7) | 22.8 (13.1–32.1) | 7.77 (3.61–14.9) | < 0.001 |
Oxygenation index (mmHg) | 400–500 | 420.0 (360.5–477.0) | 355.5 (296.0–401.0) | 439.0 (378.5–495.0) | < 0.001 |
PaO2 (mmHg) | 75–110 | 92.3 (79.2–106.0) | 75.8 (69.8–85.9) | 97.1 (84.4–108.0) | < 0.001 |
PCO2 (mmHg) | 35–45 | 39.0 (36.1–41.4) | 37.2 (33.3–39.0) | 39.6 (37.0–41.9) | < 0.001 |
Coagulation function | |||||
PT (s) | 11–15.1 | 11.8 (11.3–12.4) | 12.0 (11.3–12.6) | 11.8 (11.2–12.3) | 0.088 |
APTT (s) | 28–43.5 | 35.3 (32.5–38.5) | 36.7 (34.6–40.2) | 34.7 (31.8–38.3) | 0.002 |
D-Dimer (s) | 0–0.5 | 0.36 (0.26–0.53) | 0.53 (0.35–0.64) | 0.34 (0.25–0.50) | < 0.001 |